Related references
Note: Only part of the references are listed.Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer
Robin L. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Electron transport chain-dependent oxygen consumption in metastatic breast cancer cells
Abu-Bakr Al-Mehdi et al.
CANCER RESEARCH (2010)
Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma
Gang Niu et al.
CLINICAL CANCER RESEARCH (2010)
Comparative validation of the SP6 antibody to Ki67 in breast cancer
Lila Zabaglo et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
Isabel F. Pinhel et al.
BREAST CANCER RESEARCH (2010)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Robin L. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma
Dana Faratian et al.
HISTOPATHOLOGY (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor-Positive Breast Cancer
Frederique Penault-Llorca et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial
John A. Olson et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
R. Stuart-Harris et al.
BREAST (2008)
Short Preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
Marta Guix et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Giuseppe Viale et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
Ian E. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proliferation marker Ki-67 in early breast cancer
A Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Long-term preservation of antigenicity on tissue microarrays
KA DiVito et al.
LABORATORY INVESTIGATION (2004)
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
AE Ring et al.
BRITISH JOURNAL OF CANCER (2004)
Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint
N Holländer et al.
STATISTICS IN MEDICINE (2004)
Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling
SM Tovey et al.
BREAST CANCER RESEARCH (2004)
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
L Assersohn et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial
M Mengel et al.
JOURNAL OF PATHOLOGY (2002)
Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers
DA Arber
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2002)
Validation of tissue microarray technology in breast carcinoma
RL Camp et al.
LABORATORY INVESTIGATION (2000)
Share Paper
